Abstract

Aims We investigated the quality of life (QoL), treatment satisfaction
and perception of genetic results in participants with Maturity-Onset Diabetes
of the Young (MODY) and compared the results with those of subjects with type 1
(T1D) or type 2 (T2D) diabetes.

Methods A total of 162 adults with GCK-MODY, 62 with HNF1A-MODY and 29
with HNF4A-MODY answered the questionnaire Audit of Diabetes Dependent Quality
of Life, the Diabetes Treatment Satisfaction Questionnaire and non-validated
instrument examining the respondent’s perception of the genetic results.
Data from GCK-MODY patients were compared with 84 participants with T2D and
HNF-MODY subjects were compared with 81 participants having T1D.

Results Higher age (p=0.004), higher haemoglobin A1c
(p=0.026) and medication (p=0.019) were associated with lower
general QoL in GCK-MODY patients. In HNF-MODY patients, lower general QoL was
associated with a longer time since diagnosis (p=0.005), worse
haemoglobin bA1c (p=0.006) and insulin treatment (p=0.019).
Similar numbers of participants with GCK- and HNF-MODY considered the genetic
diagnosis of MODY to be positive, negative and without significance. The patient
with GCK-MODY did not differ from those with T2D in terms of their QoL, but they
were less satisfied with their treatment (p<0.001). QoL was better in
patients with HNF-MODY compared with patients with T1D (p=0.006), and
they did not differ in terms of treatment satisfaction.

Conclusions QoL was affected in both GCK-MODY and HNF-MODY subjects.
Apprehension of genetic diagnosis was not single-valued in MODY respondents.